Vimian Group AB/Skr VIMIAN

1D1W1MYTD1Y5YMAX

About Vimian Group AB

Vimian Group AB operates in the veterinary services industry, focusing on providing a range of specialized products and solutions for animal health. The company offers products and services across four key segments: Specialty Pharma, Diagnostics, Veterinary Services, and MedTech. These segments provide pharmaceuticals, diagnostic equipment, technology solutions, and veterinary services aimed at enhancing animal health and treatment. Founded in Sweden, Vimian Group AB is headquartered in Stockholm, from where it extends its operations globally. The company's strategic positioning is strengthened by its comprehensive range of products and services, allowing it to address diverse needs in the veterinary sector and support veterinarians through innovative solutions.
Ticker
Skr VIMIAN
Sector
Health
Primary listing
XSTO
Employees
1,300
Headquarters
Stockholm, Sweden
Website
vimian.com

Vimian Group AB Metrics

BasicAdvanced
kr 19B
45.08
kr 0.79
1.17
-

Bulls say / Bears say

Vimian’s Q2 revenue rose 17% year on year, including 12% organic growth, while adjusted EBITA also rose 17% and the margin reached 24.5%. This shows broad-based growth ahead of the animal-health market rather than growth driven only by acquisitions. (Inderes, Seeking Alpha)
The MedTech turnaround is gaining traction: organic growth reached 11% in Q2, adjusted EBITA rose 27%, and the margin expanded to 25.8%. A sustained recovery here could improve group profitability because this is one of Vimian’s largest segments. (Seeking Alpha, Investing.com)
The acquisition engine remains active, with four deals completed in 2026 and further opportunities across all four divisions. Net debt was reported at 2.1 times EBITDA, below management’s three-times ceiling, leaving room to keep adding businesses without immediately stretching the balance sheet. (Dagens industri, Seeking Alpha)
Q2 operating cash flow fell to EUR3.8m from EUR22.2m a year earlier, despite strong adjusted EBITA growth. Working capital absorbed cash, so reported earnings are not yet converting reliably into funds for debt reduction or acquisitions. (Inderes, Investing.com)
Management expects only slow single-digit organic growth in US Orthopedics during the second half of 2026 because market conditions remain soft. A weak recovery in this business could hold back MedTech and limit further margin improvement. (Quartr, Seeking Alpha)
Vimian’s 2030 target of EUR300m in adjusted EBITA requires roughly 25% annual growth from the current run rate, a demanding pace. The company has also said that 2026 margin improvement will be limited by investment in its organisation, increasing the risk that acquisitions and execution must do most of the work. (Placera, Dagens industri)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.

Funds containing Vimian Group AB

AllEURGBP
Funds
Fund name
Fund size
Skr VIMIAN weighting
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.04%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.04%
SPDR MSCI All Country World IM€SPYI
€7.5B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.